LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lissina, Anna
Languages: English
Types: Doctoral thesis
Subjects: QR180

Classified by OpenAIRE into

mesheuropmc: chemical and pharmacologic phenomena
This thesis is a collection of some of the studies I have undertaken over the last 3.5 years while working as a Research Assistant in the T cell modulation group at the Cardiff University School of Medicine. The work contained within is linked by the common theme of optimising interactions between peptide-Major Histocompatibility (pMHC) molecules, the T cell receptor (TCR), and/or coreceptor that engages these ligands. The work of the T cell modulation group is heavily focused on translational medicine. This aspect of biomedicine is also strongly encouraged by my funding body, the Wellcome Trust. My focus on translational aspects of interactions with pMHC ligands took my work in several different directions. Initially, I examined ways of improving interactions with pMHC that could be used to ameliorate the detection of antigen-specific T cells by flow cytometry. My studies have improved this technology to a point where I can now reliably claim to be able to stain the majority of relevant T cells with their cognate multimeric antigen. The approaches I helped pioneer are now in use all over the world. This work is reported in Chapters 3 and 5, and has resulted in two published primary data papers. A third paper that examines pMHC multimer valency (described in Chapter 4) is in preparation. In addition to the above-mentioned work aimed at improving T cell-related diagnostics using pMHC multimers, I also explored potential ways of improving TCR/pMHC interactions for therapeutic approaches. Specifically, I was interested in exploring whether TCRs displaying enhanced affinities for antigen would be useful in the clinic. These studies necessitated that we establish optimal TCR gene transfer protocols in Cardiff. I took the lead on these optimisation studies (Chapter 6). With the TCR gene transfer technology optimised, I was able to investigate whether increasing functional avidity of TCR-redirected T cells could be achieved by removing defined N-glycosylation sites within the TCR constant domain. This work was based on my observation that the desialylation of T cells improved the surface engagement of pMHC multimers and the recognition of cognate antigen when displayed naturally on a target cell surface. These studies were taken forward in Chapter 7. As part of my work with affinity enhanced TCRs, I was fortunate to test a novel set of TCR-based soluble therapeutic reagents comprising affinity-enhanced TCRs (Chapter 8). The enhanced TCRs were generated by phage display and directed evolution using techniques that were pioneered by my T cell modulation group colleague Jonathan Boulter while working at Avidex Ltd.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Norment, A. M., R. D. Salter, P. Parham, V. H. Engelhard and D. R. Littman (1988). Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature 336 (6194): 79-81.
    • O'Callaghan C, A., M. F. Byford, J. R. Wyer, B. E. Willcox, B. K. Jakobsen, A. J. McMichael and J. I. Bell (1999). BirA enzyme: production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation. Anal Biochem 266 (1): 9-15.
    • Obar, J. J. and L. Lefrancois (2010). Memory CD8+ T cell differentiation. Ann N YAcad Sci 1183: 251-266.
    • Oehen, S. U., P. S. Ohashi, K. Burki, H. Hengartner, R. M. Zinkernagel and P. Aichele (1994). Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell Immunol 158 (2): 342-352.
    • Oelke, M., M. V. Maus, D. Didiano, C. H. June, A. Mackensen and J. P. Schneck (2003). Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-lg-coated artificial antigen-presenting cells. N at M ed 9 (5): 619-624.
    • Ogg, G. S., A. S. King, P. R. Dunbar and A. J. McMichael (1999). Isolation of HIV-l-specific cytotoxic T lymphocytes using human leukocyte antigen-coated beads. AIDS 13 (14): 1991-1993.
    • Oji, Y., H. Inohara, M. Nakazawa, Y. Nakano, S. Akahani, S. Nakatsuka, S. Koga, A. Ikeba, S. Abeno, Y. Honjo, Y. Yamamoto, S. Iwai, K. Yoshida, Y. Oka, H. Ogawa, J. Yoshida, K. Aozasa, T. Kubo and H. Sugiyama (2003a). Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94 (6): 523-529.
    • Oji, Y., Y. Miyoshi, S. Koga, Y. Nakano, A. Ando, S. Nakatsuka, A. Ikeba, E. Takahashi, N. Sakaguchi, A. Yokota, N. Hosen, K. Ikegame, M. Kawakami, A. Tsuboi, Y. Oka, H. Ogawa, K. Aozasa, S. Noguchi and H. Sugiyama (2003b). Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 94 (7): 606-611.
    • Oji, Y., H. Yamamoto, M. Nomura, Y. Nakano, A. Ikeba, S. Nakatsuka, S. Abeno, E. Kiyotoh, T. Jomgeow, M. Sekimoto, R. Nezu, Y. Yoshikawa, Y. Inoue, N. Hosen, M. Kawakami, A. Tsuboi, Y. Oka, H. Ogawa, S. Souda, K. Aozasa, M. Monden and H. Sugiyama (2003c). Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94 (8): 712-717.
    • Okamoto, S., J. Mineno, H. Ikeda, H. Fujiwara, M. Yasukawa, H. Shiku and I. Kato (2009). Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69 (23): 9003-9011.
    • Ostergaard, H. L. and I. S. Trowbridge (1990). Coclustering CD45 with CD4 or CD8 alters the phosphorylation and kinase activity of p56lck. J Exp M ed 172 (1): 347-350.
    • Price, D. A., P. Klenerman, B. L. Booth, R. E. Phillips and A. K. Sewell (1999). Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today 20 (5): 212-216.
    • Purbhoo, M. A., J. M. Boulter, D. A. Price, A. L. Vuidepot, C. S. Hourigan, P. R. Dunbar, K. Olson, S. J. Dawson, R. E. Phillips, B. K. Jakobsen, J. I. Bell and A. K. Sewell (2001). The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 276 (35): 32786-32792.
    • Purbhoo, M. A., D. J. Irvine, J. B. Huppa and M. M. Davis (2004). T cell killing does not require the formation of a stable mature immunological synapse. Not Immunol 5 (5): 524- 530.
    • Purbhoo, M. A., Y. Li, D. H. Sutton, J. E. Brewer, E. Gostick, G. Bossi, B. Laugel, R. Moysey, E. Baston, N. Liddy, B. Cameron, A. D. Bennett, R. Ashfield, A. Milicic, D. A. Price, B. J. Classon, A. K. Sewell and B. K. Jakobsen (2007). The HLA A*0201-restricted hTERT(540- 548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. M o l Cancer Ther 6 (7): 2081-2091.
    • Purbhoo, M. A., D. H. Sutton, J. E. Brewer, R. E. Mullings, M. E. Hill, T. M. Mahon, J. Karbach, E. Jager, B. J. Cameron, N. Lissin, P. Vyas, J. L. Chen, V. Cerundolo and B. K. Jakobsen (2006). Quantifying and imaging NY-ESO-l/LAGE-l-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176 (12): 7308-7316.
    • Qian, D. and A. Weiss (1997). T cell antigen receptor signal transduction. Curr Opin Cell Biol 9 (2): 205-212.
    • Rabinowitz, J. D., C. Beeson, D. S. Lyons, M. M. Davis and H. M. McConnell (1996). Kinetic discrimination in T-cell activation. Proc Natl Acad Sci U S A 93 (4): 1401-1405.
    • Rahemtulla, A., W. P. Fung-Leung, M. W. Schilham, T. M. Kundig, S. R. Sambhara, A. Narendran, A. Arabian, A. Wakeham, C. J. Paige, R. M. Zinkernagel and et al. (1991). Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353 (6340): 180-184.
    • Ramsdell, F. and B. J. Fowlkes (1992). Maintenance of in vivo tolerance by persistence of antigen. Science 257 (5073): 1130-1134.
    • Rapoport, A. P., E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, N. Chi, B. Ratterree, M. F. Pochran, S. Natt, J. Hinkle, C. Sickles, A. Sohal, K. Ruehle, C. Lynch, L. Zhang, D. L. Porter, S. Luger, C. Guo, H. B. Fang, W. Blackwelder, K. Hankey, D. Mann, R. Edelman, C. Frasch, B. L. Levine, A. Cross and C. H. June (2005). Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat M ed 11 (11): 1230-1237.
    • Scherer, L., J. J. Rossi and M. S. Weinberg (2007). Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 14 (14): 1057-1064.
    • Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J. C. Sarria, R. Gomez-Eerland, M. Thome, T. N. Schumacher, P. Romero, D. E. Speiser, V. Zoete, O. Michielin and N. Rufer (2010). Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184 (9): 4936-4946.
    • Scholten, K. B., D. Kramer, E. W. Kueter, M. Graf, T. Schoedl, C. J. Meijer, M. W. Schreurs and E. Hooijberg (2006). Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 119 (2): 135-145.
    • Schumacher, T. N. (2002). T-cell-receptor gene therapy. N at Rev Immunol 2 (7): 512-519.
    • Sebestyen, Z., E. Schooten, T. Sals, I. Zaldivar, E. San Jose, B. Alarcon, S. Bobisse, A. Rosato, J. Szollosi, J. W. Gratama, R. A. Willemsen and R. Debets (2008). Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol 180 (11): 7736-7746.
    • Sebzda, E., S. Mariathasan, T. Ohteki, R. Jones, M. F. Bachmann and P. S. Ohashi (1999). Selection of the T cell repertoire. Annu Rev Immunol 17: 829-874.
    • Sebzda, E., V. A. Wallace, J. Mayer, R. S. Yeung, T. W. Mak and P. S. Ohashi (1994). Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science 263 (5153): 1615-1618.
    • Sedlik, C., G. Dadaglio, M. F. Saron, E. Deriaud, M. Rojas, S. I. Casal and C. Leclerc (2000). In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74 (13): 5769-5775.
    • Sercarz, E. E. and E. Maverakis (2003). Mhc-guided processing: binding of large antigen fragments. N at Rev Immunol 3 (8): 621-629.
    • Sewell, A. K. (2002). Breaking the kinetic window of T-cell activation. Trends Immunol 23 (2): 67.
    • Sewell, A. K., G. C. Harcourt, P. J. Goulder, D. A. Price and R. E. Phillips (1997). Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. EurJ Immunol 27 (9): 2323-2329.
    • Shah, N. P., C. Tran, F. Y. Lee, P. Chen, D. Norris and C. L. Sawyers (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (5682): 399-401.
    • Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old and R. D. Schreiber (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (6832): 1107-1111.
    • van der Merwe, P. A. (2000). Modeling costimulation. N at Immunol 1 (3): 194-195.
    • van der Merwe, P. A. (2001). The TCR triggering puzzle. Immunity 14 (6): 665-668.
    • van der Merwe, P. A. and S. J. Davis (2003). Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21: 659-684.
    • Van Laethem, F., S. D. Sarafova, J. H. Park, X. Tai, L. Pobezinsky, T. I. Guinter, S. Adoro, A. Adams, S. O. Sharrow, L. Feigenbaum and A. Singer (2007). Deletion of CD4 and CD8 coreceptors permits generation of alphabetaT cells that recognize antigens independently of the MHC. Immunity 27 (5): 735-750.
    • van Loenen, M. M., R. de Boer, A. L. Amir, R. S. Hagedoorn, G. L. Volbeda, R. Willemze, J. J. van Rood, J. H. Falkenburg and M. H. Heemskerk (2010). Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A 107 (24): 10972-10977.
    • Varela-Rohena, A., C. Carpenito, E. E. Perez, M. Richardson, R. V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R. G. Carroll, C. H. June and J. L. Riley (2008a). Genetic engineering of T cells for adoptive immunotherapy. Immunol Res 42 (1-3): 166-181.
    • Varela-Rohena, A., P. E. Molloy, S. M. Dunn, Y. Li, M. M. Suhoski, R. G. Carroll, A. Milicic, T. Mahon, D. H. Sutton, B. Laugel, R. Moysey, B. J. Cameron, A. Vuidepot, M. A. Purbhoo, D. K. Cole, R. E. Phillips, C. H. June, B. K. Jakobsen, A. K. Sewell and J. L. Riley (2008). Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat M ed 14 (12): 1390-1395.
    • Varela-Rohena, A., P. E. Molloy, S. M. Dunn, Y. Li, M. M. Suhoski, R. G. Carroll, A. Milicic, T. Mahon, D. H. Sutton, B. Laugel, R. Moysey, B. J. Cameron, A. Vuidepot, M. A. Purbhoo, D. K. Cole, R. E. Phillips, C. H. June, B. K. Jakobsen, A. K. Sewell and J. L. Riley (2008b). Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat M ed 14 (12): 1390-1395.
    • Varki, A., Ed. (2009). The essentials of glvcobiology. New York Veillette, A., M. A. Bookman, E. M. Horak and J. B. Bolen (1988a). The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 55 (2): 301-308.
    • Veillette, A., I. D. Horak, E. M. Horak, M. A. Bookman and J. B. Bolen (1988b). Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation. M ol Cell Biol 8 (10): 4353-4361.
    • Venturi, V., K. Kedzierska, M. M. Tanaka, S. J. Turner, P. C. Doherty and M. P. Davenport (2008). Method for assessing the similarity between subsets of the T cell receptor repertoire. J Immunol Methods 329 (1-2): 67-80.
    • Wooldridge, L., T. J. Scriba, A. Milicic, B. Laugel, E. Gostick, D. A. Price, R. E. Phillips and A. K. Sewell (2006). Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. EurJ Immunol 36 (7): 1847-1855.
    • Wooldridge, L., H. A. van den Berg, M. Glick, E. Gostick, B. Laugel, S. L. Hutchinson, A. Milicic, J. M. Brenchley, D. C. Douek, D. A. Price and A. K. Sewell (2005). Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 280 (30): 27491-27501.
    • Wu, H., P. D. Kwong and W. A. Hendrickson (1997). Dimeric association and segmental variability in the structure of human CD4. Nature 387 (6632): 527-530.
    • Wu, W., P. H. Harley, J. A. Punt, S. O. Sharrow and K. P. Kearse (1996). Identification of CD8 as a peanut agglutinin (PNA) receptor molecule on immature thymocytes. J Exp M ed 184 (2): 759-764.
    • Wyer, J. R., B. E. Willcox, G. F. Gao, U. C. Gerth, S. J. Davis, J. I. Bell, P. A. van der Merwe and B. K. Jakobsen (1999). T cell receptor and coreceptor CD8 alphaalpha bind peptideMHC independently and with distinct kinetics. Immunity 10 (2): 219-225.
    • Wynn, R. F., P. D. Arkwright, T. Haque, M. I. Gharib, G. Wilkie, M. Morton-Jones and D. H. Crawford (2005). Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 6 (5): 344-346.
    • Xiao, Z., M. F. Mescher and S. C. Jameson (2007). Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp M ed 204 (11): 2667-2677.
    • Xiong, Y., P. Kern, H. Chang and E. Reinherz (2001). T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4. J Biol Chem 276 (8): 5659- 5667.
    • Xu, L., W. Xu, S. Qiu and S. Xiong (2010). Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 135 (3): 466-475.
    • Xu, X. N., M. A. Purbhoo, N. Chen, J. Mongkolsapaya, J. H. Cox, U. C. Meier, S. Tafuro, P. R. Dunbar, A. K. Sewell, C. S. Hourigan, V. Appay, V. Cerundolo, S. R. Burrows, A. J. McMichael and G. R. Screaton (2001). A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class l/peptide complex. Immunity 14 (5): 591-602.
    • Xu, Z. and A. Weiss (2002). Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3 (8): 764-771.
    • Xue, S., R. Gillmore, A. Downs, A. Tsallios, A. Holler, L. Gao, V. Wong, E. Morris and H. J. Stauss (2005). Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol 139 (2): 167-172.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT

Cite this article